In addition, Chen et al reported more frequent upregulation of PD‐L1 on tumor cells in EBV+ DLBCL and EBV+ post‐transplant LPDs (100% and 60% of cases, respectively).17 One potential explanation for the discrepancy with our data is the use of different antibodies. This evidence concerns the gene CD274 and diffuse large B-cell lymphoma.